Posted in | News | Nanomedicine

Blend Secures $21 Million Funding to Create mBDCs Encapsulated in Nanoparticles

Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.

The proceeds of the financing will enable Blend to fully exploit its proprietary Pentarin™ platform, unveiled today, which creates novel, miniaturized biologic drug conjugates encapsulated in nanoparticles, representing a new class of cancer therapeutics. Including the $21 million announced today, Blend has obtained a total of $39.8 million in funding to date. Blend is backed by top-tier venture investors, including New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.

Blend also announced today that it has secured a technology license from a private biotechnology company for novel bi-podal biologic targeting ligands that is an exclusive license in the field of oncology. The in-licensing of this ligand technology is a strategic asset for Blend to develop a robust pipeline of Pentarins. Targeting ligands are one of the core components of Pentarins and Blend’s platform enables the conjugation of the targeting ligand to a therapeutic payload with a chemical linker to create miniaturized biologic drug conjugates (mBDCs), and encapsulates the mBDCs in proprietary nanoparticles to create Pentarins. Together, the components of the Pentarins have distinct yet synergistic anticancer capabilities: the nanoparticle enables high therapeutic concentration at the tumor site; the small size of mBDCs allows for effective penetration and distribution deep into the tumor tissue; the ligand’s targeting ability allows for specific binding to tumor cells; and the cell-killing payload is released inside the cancer cells.

“We are excited to unveil our Pentarin platform as a product engine that creates a new class of cancer therapeutics, and an exceptional opportunity to create value for patients as well as our investors. We look forward to conducting IND-enabling studies to advance our lead Pentarin drug program BTP-277 and completing IND enabling studies of our novel, personalized cisplatin, BTP-114, from our longstanding R&D in platinum drugs” said Richard Wooster, PhD, President of Research and Development of Blend. “Pentarins are an entirely new class of biologic drug conjugates specifically designed for solid tumors, and represent a significant advance in the field since the first development of antibody drug conjugates 35 years ago. We have created Pentarins to have a unique structure, miniaturization and nanoparticle encapsulation that enable the selective targeting of cancer cells and unprecedented penetration deep into tumor tissue, with the aim to improve the treatment of solid tumor cancers for patients.”

In the advancement of Blend’s pipeline of novel drug programs, the proceeds from the financing will be used to further develop the company’s lead program, BTP-114, through studies to enable filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). Based on Blend’s historical R&D in novel platinum drug discovery and distinct from the Pentarin platform, BTP-114 is a novel, personalized cisplatin prodrug with novel chemistry designed to preferentially accumulate platinum at the tumor site, deliver a concentrated therapeutic effect and target specific cancers. The funding will also enable Blend to advance its first Pentarin drug candidate, BTP-277, to IND enabling studies as well as exploring other internal Pentarin programs. In addition, Blend anticipates developing Pentarins in partnership with biotechnology and pharmaceutical collaborators who have their own proprietary targeting protein scaffolds which can be deployed to create novel biologic drug conjugates using Blend’s Pentarin platform.

“Blend has made enormous progress to deploy its suite of technologies and oncology R&D expertise to create the valuable Pentarin platform and a pipeline that has come into view and is recognized by Blend’s investors,” said Omid Farohkzad, MD, Founder and Chairman of Blend Therapeutics and Associate Professor at Harvard Medical School. “While the company’s mission has remained steadfast – to develop cancer therapies with superior efficacy and selectivity that push conventional therapeutic boundaries – Blend has quietly consolidated its capabilities into the technologically superior Pentarin platform and implemented a thorough and comprehensive intellectual property strategy to advance the field of biologic drug conjugates and have much broader potential impact for patients with solid tumors.”


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.